Callos Andrew 4

What Happened
Andrew Callos, EVP and Chief Commercial Officer of Cytokinetics (CYTK), disposed of 2,582 shares on 2026-03-09 in an open-market/private sale at $60.72 per share for total proceeds of $156,779. The filing notes this was a sell-to-cover transaction to satisfy tax withholding obligations related to vested restricted stock units (RSUs), a routine post-vesting sale rather than a discretionary investment sell-off.

Key Details

• Transaction date: 2026-03-09; filed with the SEC on 2026-03-10.
• Shares sold: 2,582 at $60.72 per share; proceeds $156,779.
• Transaction type/code: Sale (S) — noted as open-market or private sale.
• Footnote: F1 — sell-to-cover to satisfy company tax withholding on vested RSUs.
• Shares owned after transaction: not specified in the filing.
• Filing timeliness: reported the next day (appears timely, no late-filing indicator noted).

Context
Sell-to-cover transactions are common when RSUs vest and typically reflect tax withholding rather than a directional bet on the stock. For retail investors, purchases by insiders are often more informative about confidence in the company; routine tax-related sales should be interpreted accordingly.